Stonewise
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An AI-driven drug discovery company targeting novel small molecules for oncology and immunology.
OncologyImmunology
Technology Platform
A proprietary AI and machine learning platform for de novo small molecule design and optimization.
Opportunities
Potential to form lucrative partnerships with large pharma companies seeking to augment their R&D productivity with AI.
Risk Factors
Risk of platform validation failure if its internally discovered molecules do not progress successfully through clinical development.
Competitive Landscape
Operates in the highly competitive global AI drug discovery arena, requiring constant innovation to differentiate from both Western and domestic Chinese platforms.